The size of xenografts of ursolic acid group as well as positive control group reduced remarkably (P < 0.05). The

tumor inhibition rate was 53.7% and 39.2%, respectivly. The relative tumor volume (RTV) of ursolic acid group and the positive control group was 33.16 ± 22.36, 21.61 ± 12.88, respectively. They were significantly less than the counterpart of the negative control group (62.09 ± 32.80) (p < 0.05). The relative tumor proliferation rate of above two groups was both below 60%. Conclusion: Ursolic acid showed a potent inhibition to the growth of human hepatoma SMMC – 7721 xenografts in nude mice. Key Word(s): 1. ursolic acid; 2. animal model; 3. anti-tumor; 4. inhibition rate; Presenting Author: NINGNING ZHANG Additional Authors: LU WEI Corresponding Author: LU WEI Affiliations: Tianjin Second People’s Hospital Objective: To determine the tumor recurrence, safety, and STI571 clinical trial survival outcomes of HCC patients with chronic hepatitis C (genotype 1) infection after receiving radiofrequency ablation (RFA) and antiviral therapy using peg-alfa interferon and weight Selleck CH5424802 based ribavirin.

Methods: Using our institution’s database, we identified all patients with chronic Hepatitis C (HCV) genotype 1 and small HCC (less than 3.0 cm) between December 2007 – December 2010. The following data was extracted; sustained virological rate (SVR), tumor necrosis rate and tumor recurrent rate, and 1-year survival rate. HCC recurrence and monitoring was done using serum a-fetoprotein (AFP) test and radiological findings

Results: During the study period, there were 75 patients (42 males, 33 females, age 43 years (32–54) with HCC (≤3 cm) and HCV (genotype 1). We divided the patients into two groups: control group (n = 33) received RFA only and treatment group (n = 42) received 上海皓元医药股份有限公司 RFA and peg-alfa interferon with weight based ribavirin. The tumor complete necrosis rate at three months in the control group was 24.24% versus Rx group was 50% (P < 0.05). The one-year viral suppression in the control group was 30.3% versus Rx group 64.28% (P < 0.05). The HCC recurrence rate in the control group was 38.39% versus Rx group 7.1% (P < 0.05). The one-year survival rate was 30.3% in control group versus Rx group 61.9% (P < 0.05). Conclusion: The above results demonstrate potential benefits of adding antiviral therapy and suppressing HCV virus in patients with compensated cirrhosis and small HCC undergoing RFA. Further trials involving larger number of patients are needed to delineate the overall impact of HCV eradication in the patient with compensated cirrhosis and HCC. As the antiviral therapies continue to evolve future trials may offer an opportunity at viral eradication prior to LTx thus improving long term outcomes. Key Word(s): 1. HCC; 2. CHC; 3. RFA; 4.